AGMB.US AgomAb Therapeutics NV American Depositary Shares

Healthcare Biotechnology USA Stocks
6.36 USD
Close of Nov 13, 2026
6.19 17.82
Market cap
USD 313M
P/E
-
P/B
1.15x
ROE
-17.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.

Is AGMB.US undervalued?

Graham number

The Graham number of AgomAb Therapeutics NV American Depositary Shares cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AgomAb Therapeutics NV American Depositary Shares fundamental analysis

No fundamental analysis for AgomAb Therapeutics NV American Depositary Shares yet.

AgomAb Therapeutics NV American Depositary Shares stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AgomAb Therapeutics NV American Depositary Shares

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 fo…

Full company profile